[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640712":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":33,"studyPopulation":25,"armGroups":34,"interventions":41,"overallOfficials":25,"centralContacts":25,"locations":46,"responsibleParty":67,"collaborators":69,"id":73,"slug":25,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":25,"enrollmentInfo":81,"targetDuration":25,"studyType":84,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":49,"whyStopped":25,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Northwell Health","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"To prospectively assess durability of PFA ablation","Durability analysis will include % of patients with any PV reconnection, % of PVs reconnected, and % of patients with recovered conduction in the endocardial posterior wall (if posterior wall isolation performed at the index procedure).","From Index Ablation to Subsequent Re-mapping procedure with concomitant LAAO implant. The remapping procedure will occur approximately 30-180 days after the index ablation.",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"To assess arrhythmia-free survival in patients with confirmed durable PVI (+\u002F-) posterior wall isolation","Patients demonstrating durable PVI (+\u002F- posterior wall isolation) confirmed during remapping procedure will be monitored for arrhythmia recurrence. Arrhythmia recurrence will be evaluated based on 1-week extended Holter monitoring performed at 6 months and 12 months post ablation.","6 months and 12 months post remapping procedure",{"measure":19,"description":20,"timeFrame":21},"Assess clinical outcomes following strategy of LAAO implant and potential for repeat AF ablation performed as consecutive procedures.","Clinical outcomes following this novel prospective dual-procedure strategy will be analyzed, including assessment of clinical AT\u002FAF recurrence and symptomatic arrhythmia recurrence.","From enrollment\u002Findex ablation to the 12month follow up post remapping procedure",{"measure":23,"description":24,"timeFrame":21},"Assess procedure related outcomes following strategy of LAAO implant and potential for repeat AF ablation performed as consecutive procedures.","Procedural related outcomes following this novel prospective dual-procedure strategy will be analyzed, including assessment of ischemic stroke\u002FTIA, bleeding complications, hospitalizations, and death.",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":29,"primaryPurpose":30,"observationalModel":25,"timePerspective":25,"maskingInfo":31},"NA","SINGLE_GROUP","Single-arm, open label","TREATMENT",{"masking":32,"maskingDescription":25,"whoMasked":25},"NONE","Atrial fibrillation is a heart condition where the heart beats rapidly and\u002For irregularly. An ablation procedure is a form of treatment for atrial fibrillation to try to maintain or return the heart to a normal rhythm (called sinus rhythm). Ablation procedures can be done using heat (radiofrequency energy), cold (cryo energy), or electrical energy emitted by pulses (pulsed field ablation). Pulsed field ablation (PFA) is an invasive treatment procedure for which the doctor will deliver controlled energy through a PFA Catheter to destroy or scar the specific heart tissue causing the abnormal electrical signals. This scar helps to interrupt the abnormal electrical pathways and restore a normal heart rhythm. Ablation procedures are performed according to the standard of care.\n\nThe purpose of this study is to research the durability of receiving a PFA for the treatment of atrial fibrillation during a subsequent procedure performed at least 30 days after the initial ablation. The remapping procedure will utilize integrated electroanatomic mapping and intracardiac echocardiography to determine the index procedure technical success independent of arrhythmia recurrence.",[35],{"label":36,"type":37,"description":38,"interventionNames":39},"Single-arm, open label - all enrolled subjects","EXPERIMENTAL","Remapping procedure with LAAO Implant with or without additional ablation.",[40],"Device: Remapping Procedure",[42],{"type":43,"name":44,"description":38,"armGroupLabels":45,"otherNames":25},"DEVICE","Remapping Procedure",[36],[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"South Shore University Hospital","RECRUITING","Bay Shore","New York","11706","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-73.24539,40.7251,{"lat":59,"lon":58},[62],{"name":63,"role":64,"phone":65,"phoneExt":25,"email":66},"Rachel Gentles","CONTACT","631-968-3016","rgentles1@northwell.edu",{"type":68,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[70],{"name":71,"class":72},"Boston Scientific Corporation","INDUSTRY","100640712",false,"NCT07620262","Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study","PRECLUDE","Inclusion Criteria:\n\n* Participant is ≥ 18 years of age, or older if specified by local law\n* Participant has documented paroxysmal or persistent atrial fibrillation not related to a reversible cause\n* Participant has AF-related symptoms, and\u002For presence of CHF or LV dysfunction\n* Participant has a CHADSVASc\\>=3\n* There is appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation for thromboembolic protection\n* Participant is willing and capable of providing informed consent\n* Participant is willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center\n\nExclusion Criteria:\n\n* Participant has had prior AF ablation (including surgical ablation)\n* Participant has had prior left atrial appendage occlusion or closure\n* Participant has an intracardiac mass or thrombus\n* Participant has had a bleeding disorder or inability to tolerate short-term oral anticoagulation\n* Participant has a life expectancy \\\u003C 1 year\n* Participant has had recent MI, CVA, or cardiac surgery in preceding 90 days\n* Participant has an inability to comply with outpatient follow-up, or cognitive impairment that precludes understanding of procedure risks and benefits Participant has an active systemic infection\n* Participant has a mechanical heart valve through which the catheter must pass, or severe mitral stenosis\n* Participant has a vena cava embolic protection filter devices and\u002For known femoral thrombus who require catheter insertion from the femoral approach\n* Participant had congenital heart disease where the underlying abnormality increases the risk of ablation (e.g. severe rotational anomalies of the heart or great vessels)\n* Participant is woman of childbearing potential who is pregnant, lactating, not using a reliable form of contraception, or who is planning to become pregnant during the anticipated study period","ALL","18 Years",{"count":82,"type":83},50,"ESTIMATED","INTERVENTIONAL",[27],"This is a single-arm, open label, clinical outcome study to research the durability (success) of receiving a pulsed field ablation (PFA) per standard of care for treatment of atrial fibrillation during a subsequent procedure for the insertion of a left atrial appendage occlusion (LAAO) device. The reassessment of the initial ablation will be performed with or without additional ablation if needed.",[88],"Atrial Fibrillation (AF)",[90,91,92,93],"Ablation","Atrial Fibrilation","Re-mapping","LAAO Device","2026-05-27",{"date":96,"type":97},"2026-06-02","ACTUAL",{"date":99,"type":97},"2026-05-01",{"date":101,"type":83},"2028-07",{"name":5,"class":6},1]